Human Infections with Borna Disease Virus 1 (BoDV-1) Primarily Lead to Severe Encephalitis: Further Evidence from the Seroepidemiological BoSOT Study in an Endemic Region in Southern Germany.

Autor: Bauswein M; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany., Eidenschink L; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany., Knoll G; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany., Neumann B; Department of Neurology, Donau-Isar-Klinikum Deggendorf, 94469 Deggendorf, Germany.; Department of Neurology, University of Regensburg, Bezirksklinikum, 93053 Regensburg, Germany., Angstwurm K; Department of Neurology, University of Regensburg, Bezirksklinikum, 93053 Regensburg, Germany., Zoubaa S; Department of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany., Riemenschneider MJ; Department of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany., Lampl BMJ; Regensburg Department of Public Health, 93059 Regensburg, Germany.; Department of Epidemiology and Preventive Medicine, University of Regensburg, 93053 Regensburg, Germany., Pregler M; Regensburg Department of Public Health, 93059 Regensburg, Germany., Niller HH; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany., Jantsch J; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, 50935 Cologne, Germany., Gessner A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany., Eberhardt Y; Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany., Huppertz G; Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany., Schramm T; Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany., Kühn S; Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany., Koller M; Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany., Drasch T; Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany., Ehrl Y; Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany., Banas B; Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany., Offner R; Institute of Clinical Chemistry and Laboratory Medicine, Department of Transfusion Medicine, University Hospital Regensburg, 93053 Regensburg, Germany., Schmidt B; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany., Banas MC; Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2023 Jan 09; Vol. 15 (1). Date of Electronic Publication: 2023 Jan 09.
DOI: 10.3390/v15010188
Abstrakt: More than 40 human cases of severe encephalitis caused by Borna disease virus 1 (BoDV-1) have been reported to German health authorities. In an endemic region in southern Germany, we conducted the seroepidemiological BoSOT study ("BoDV-1 after solid-organ transplantation") to assess whether there are undetected oligo- or asymptomatic courses of infection. A total of 216 healthy blood donors and 280 outpatients after solid organ transplantation were screened by a recombinant BoDV-1 ELISA followed by an indirect immunofluorescence assay (iIFA) as confirmatory test. For comparison, 288 serum and 258 cerebrospinal fluid (CSF) samples with a request for tick-borne encephalitis (TBE) diagnostics were analyzed for BoDV-1 infections. ELISA screening reactivity rates ranged from 3.5% to 18.6% depending on the cohort and the used ELISA antigen, but only one sample of a patient from the cohort with requested TBE diagnostics was confirmed to be positive for anti-BoDV-1-IgG by iIFA. In addition, the corresponding CSF sample of this patient with a three-week history of severe neurological disease tested positive for BoDV-1 RNA. Due to the iIFA results, all other results were interpreted as false-reactive in the ELISA screening. By linear serological epitope mapping, cross-reactions with human and bacterial proteins were identified as possible underlying mechanism for the false-reactive ELISA screening results. In conclusion, no oligo- or asymptomatic infections were detected in the studied cohorts. Serological tests based on a single recombinant BoDV-1 antigen should be interpreted with caution, and an iIFA should always be performed in addition.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje